Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 16, 2019

Sanofi to use Biomunex’s BiXAb platform to generate antibody therapeutics

Biomunex Pharmaceuticals has signed a licensing agreement with Sanofi for the development of bi-specific and multi-specific antibody therapeutics.

Image: Sanofi will use Biomunex’s BiXAb platform to generate and optimize antibody therapeutics. Photo: courtesy of Baitong333 / FreeDigitalPhotos.net.